Airway Therapeutics Patent Portfolio Analysis

A single pulse, and a local syndicate

The $24M Series E came from CincyTech, Cincinnati Children's and QCA Ventures. That is a hometown table. Airway Therapeutics was founded in 2011 to carry forward the pulmonary research program of Cincinnati Children's Hospital Medical Center, and the money has stayed close to the source. Fourteen years between founding and this pulse is a long runway for a company whose entire technical premise rests on one human protein.

The hiring tells you where the work sits now. One open role, a Clinical Research Associate, based in Madrid. Not a research build-out. Not a platform expansion. A single clinical operations seat in Europe, which is what a company looks like when the science has been settled and the trials are the remaining question. Everything upstream of that was decided years earlier, and the filing record is where you read it.

Four solid ticks, two thin, one molecule

Six families since 2018. Two filed in 2018, two in 2019, one in 2021, one in 2024. Four are granted and enforceable today. Two remain published and pending, and the first of those could issue at any point. Coverage runs across AU, CN, EP, JP, US and WO, which is a deliberate international spread rather than a domestic filing with optional extensions bolted on afterward.

The titles tell one story. Treating premature newborn infants with recombinant human surfactant protein D. Characterizing SP-D oligomers. Using surfactant protein D against viral infections. Therapy, analytics and a second indication, all built on the same molecule. The claims sit in medicinal preparations and in enzymes, cells and genetic engineering, which is the signature of a company that had to invent both the biologic and the way to measure it.

Six families is not a portfolio strategy. It is a single conviction, filed six ways.

Thirty-one names, one constant presence

Thirty-one inventors are named across six families. That is an unusually wide bench for a portfolio this compact, and it reflects the hospital research origin: protein work of this kind pulls in expression, purification, assay development and clinical design, each with its own contributors. Most of those names appear once. The families are not repetitions of a single idea by a single hand.

Susan Rosenbaum Jan is on four of the six, recorded in the record under both name orderings. Frederick Gyapon Quast appears on two. That is the shape of a portfolio with one scientific author and a rotating cast of specialists around her. When continuity of inventorship runs through two thirds of the families across six years, the filings read as a sustained program rather than a set of opportunistic captures.

The giants next door are farming, not breathing

On the same scale, Airway Therapeutics is a dot. University of California filed 661 families in these CPC groups over five years. Huazhong Agricultural University, 637. China Agricultural University, 583. Zhejiang University, 541. Jiangnan University, 512. South China Agricultural University, 509. A61K and C12N are among the most heavily worked classifications in the system, and volume here is not a meaningful comparison.

Read the names instead of the numbers. Four of the top six are agricultural universities. They share a classification code with Airway Therapeutics, not a research question. Crowding at the CPC level tells you the neighbourhood is busy; it does not tell you anyone else is working on recombinant human SP-D for premature infants. In a space this dense, what matters is the specificity of the claim, not the count.

Who reads these filings closely enough to cite

Four organizations point back. Sekisui Medical cites the portfolio four times, Glycotope twice, National Jewish Health once, and Xuanwu Hospital Capital Medical University once. Small numbers, but the composition is informative. A diagnostics company, a glycoprotein specialist, a respiratory research institution and a clinical hospital. None of them are the agricultural filers who dominate the classification.

That set maps onto the portfolio's two halves. Diagnostics and glycoprotein work track the SP-D oligomer characterization filings. The respiratory and hospital citations track the therapeutic ones. Citation from parties whose own work sits in the same specific subject area is a stronger signal of relevance than citation volume from anywhere. The neighbourhood is loud, but the people actually reading this file are the right ones.

Citation by four specialists beats citation by four hundred strangers.

What a thin portfolio has to carry

The last public filing is dated 2024-11-01, twenty-one months before this round. Anything filed since is still inside the publication window and invisible. So the record ends at six families: four granted and enforceable, two pending, spread over six jurisdictions, sustained by one lead inventor across six years, and pointed at a single protein with a therapeutic use, an analytical method and a second viral indication.

That is the whole moat, and it is narrower than most. Narrow is not the same as weak. A portfolio built around one molecule, filed early, granted in the major markets and cited by the handful of organizations working in the same specific area, is defensible in precisely the way a sprawling one often is not. The question is whether the molecule is right.